Eli Lilly and Company is eyeing India as a pivotal global export base for its blockbuster drug Mounjaro, leveraging a $1 billion investment in contract manufacturing to fuel surging international shipments.
Winselow Tucker, Lilly India’s president, revealed plans at the BioAsia conference to integrate local production into the company’s worldwide supply chain, exporting India-made drugs amid doubled Mounjaro sales post-launch. This shift taps India’s robust contract manufacturing ecosystem for injectables and vials, easing global shortages driven by obesity treatment demand.
From a logistics standpoint, the strategy promises heightened cargo volumes through key Indian ports like Chennai, Nhava Sheva (JNPT), and Mundra, which handle pharma exports efficiently via cold chain facilities. Analysts forecast increased reefer container traffic and faster customs clearances under India’s PLI scheme, strengthening maritime links to high-demand markets in the US, Europe, and Southeast Asia
Lilly’s new Hyderabad oversight hub for manufacturing and quality will streamline supply networks, positioning India as a competitive alternative to traditional hubs like Singapore. This pharma boom could add significant TEUs to India’s outbound shipping, benefiting carriers and terminal operators.
